These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9305716)

  • 61. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens.
    Haagsma EB; Van Den Berg AP; Kleibeuker JH; Slooff MJ; Dijkstra G
    Aliment Pharmacol Ther; 2003 Jul; 18(1):33-44. PubMed ID: 12848624
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients.
    Montenovo MI; Jalikis FG; Li M; Yeh M; Dick A; Hansen R; Reyes JD
    Exp Clin Transplant; 2017 Aug; 15(4):425-431. PubMed ID: 27309029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
    Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW
    Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report.
    Pirenne J; Aerts R; Koshiba T; Van Gelder F; Roskams T; Schetz M; Verhaegen M; Lauwers P; Fevery J; Nevens F
    Clin Transplant; 2003 Jun; 17(3):177-82. PubMed ID: 12780665
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation.
    Langrehr JM; Schneller A; Guckelberger O; Lohmann R; Neumann U; Jonas S; Klupp J; Settmacher U; Knoop M; Bechstein WO; Neuhaus PJ
    Transplant Proc; 1998 Jun; 30(4):1439-40. PubMed ID: 9636583
    [No Abstract]   [Full Text] [Related]  

  • 67. Influence of antilymphocyte globulin upon the incidence of malignancies after kidney transplantation.
    Luciani J; Benalia H; Bitker MO; Mouquet C; Chartier-Kastler E; Ourhama S; Jacobs C; Chatelain C; Viars P
    Transplant Proc; 1993 Jun; 25(3):2302. PubMed ID: 8516907
    [No Abstract]   [Full Text] [Related]  

  • 68. Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults.
    Zhu X; Guan J; Xu J; Wei J; Jiang L; Yin J; Zhao L; Zhang Y
    Blood Cells Mol Dis; 2014 Sep; 53(3):157-60. PubMed ID: 24931461
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.
    Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
    Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
    Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Occurrence of suspicious changes in cervix cytology in women after liver transplantation].
    David M; Olbrich C; Neuhaus R; Lichtenegger W
    Geburtshilfe Frauenheilkd; 1995 Aug; 55(8):431-4. PubMed ID: 7557217
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.
    Lan X; Liu MG; Chen HX; Liu HM; Zeng W; Wei D; Chen P
    World J Gastroenterol; 2014 Sep; 20(34):12330-40. PubMed ID: 25232269
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antibody induction therapy for lung transplant recipients.
    Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
    Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants.
    Raofi V; Holman DM; Coady N; Vazquez E; Dunn TB; Bartholomew AM; Pollak R; Benedetti E
    Am J Surg; 1999 Apr; 177(4):299-302. PubMed ID: 10326847
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P; Felipe C; Ferreira A; Cristelli M; Viana L; Mansur J; Basso G; Hannun P; Aguiar W; Tedesco Silva H; Medina-Pestana J
    Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus.
    Ericzon BG; Eusufzai S; Söderdahl G; Duraj F; Einarsson K; Angelin B
    Transplantation; 1997 Jan; 63(1):74-80. PubMed ID: 9000664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.